China Meheco Group Co

China Meheco Group Co EBITDA per Employee

The EBITDA per Employee of China Meheco Group Co (600056.SS) as of Oct 22, 2026 is 141,341.09 CNY. In the previous year, EBITDA per Employee was 175,159.35 CNY — a change of -19.31% (lower).

EBITDA per Employee

141,341.09CNY

YoY

-19.31%

Last updated:

EBITDA per Employee of China Meheco Group Co is 2025 141,341.09 CNY. EBITDA per Employee of China Meheco Group Co was 2024 175,159.35 CNY. It decreases by -19.31% lower compared to the previous year.

The China Meheco Group Co EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
236,436.28 CNY
Jan 1, 2019
234,322.54 CNY
Jan 1, 2020
246,263.26 CNY
Jan 1, 2021
186,649.68 CNY
Jan 1, 2022
172,716.83 CNY
Jan 1, 2023
241,422.78 CNY
Jan 1, 2024
175,159.35 CNY
Jan 1, 2025
141,341.09 CNY
The China Meheco Group Co EBITDA per Employee history
YEAREBITDA per EmployeeYoY
141,341.09CNY-19.31%
175,159.35CNY-27.45%
241,422.78CNY+39.78%
172,716.83CNY-7.46%
186,649.68CNY-24.21%
246,263.26CNY+5.10%
234,322.54CNY-0.89%
236,436.28CNY-7.18%
254,716.73CNY+39.49%
182,603.71CNY+50.66%
121,201.17CNY+22.38%
99,039.62CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

China Meheco Group Co Stock analysis

What does China Meheco Group Co do? China Meheco Group Co., Ltd. generates revenue through its Industrial Pharmaceutical segment, which manufactures and distributes chemical preparations, chemical bulk drugs, biological products, Chinese patent medicine, and herbal decoction pieces. The Commercial Pharmaceutical segment focuses on wholesale and distribution of pharmaceuticals and medical devices. The Trading segment handles international exporting and medical resourcing introduction. The company serves healthcare providers, hospitals, and pharmacies through its wholesale operations, targeting the pharmaceutical and medical device markets in China and internationally. The Industrial Pharmaceutical segment produces chemical preparations, chemical bulk drugs, biological products, Chinese patent medicine, and herbal decoction pieces for distribution. The Commercial Pharmaceutical segment supplies pharmaceuticals and medical devices to healthcare institutions and retailers. The Trading segment facilitates international exports of pharmaceutical products and introduces medical resources globally, catering to global healthcare markets. China Meheco's revenue streams are derived from the sale of pharmaceutical products across its three segments. The Industrial segment manufactures and sells chemical and traditional Chinese medicine products, while the Commercial segment distributes these products through wholesale channels. The Trading segment earns from exporting pharmaceuticals and managing international medical resource procurement for global clients. China Meheco Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about China Meheco Group Co stock

EBITDA per Employee of China Meheco Group Co is 141,341.09 CNY in 2025.

EBITDA per Employee of China Meheco Group Co changed from 175,159.35 CNY to 141,341.09 CNY, representing a -19.31% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee China Meheco Group Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's China Meheco Group Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — China Meheco Group Co

All Key Metrics — China Meheco Group Co